C3bot peptides as drugs for the treatment of traumatic or degenerative neuronal injury

<b>Background:</b>

Peptide fragments of the C3 exoenzyme of Clostridium botulinum have been found to have neuritogenic effects on neurons as well as regenerative proper-ties in an animal model (mouse). The peptides represent promising drug candidates for the treatment of neurodegenerative disorders such as Morbus Alzheimer, Parkinson, Huntington chorea but also for spinal cord injury and traumatic brain injury.enic effects on neurons as well as regenerative properties in an animal model (mouse).<br><br> <b>Technology:</b> We offer neuron-specific short peptides for the treatment of neurodegene-rative disorders. Whereas a 26mer peptide stimulates both, dendritic and axonal growth, a 15mer peptide selectively promotes axonal growth. Both, the 15mer and the 26mer peptide trigger a strong transient activation of RhoA which mimics the physiological conditions of RhoA activation / inactivation cycles. These properties make the peptides suitable for repeated administration and long term treatments. As the peptides only act on neurons and not on microglia or astrocytes, there is no risk for neuronal inflammation or glia scar formation.<br><br> <b>Benefits:</b><br> <ul> <li>Physiological acting neuritogenic drug – small size and effective in nanomolar concentrations</li> <li>Act neuron-specific – reduced risk for neuronal inflammation or glia scar formation</li> <li>Short peptides with low antigenicity and good kinetics </li> <li>Broad application areas: Spinal cord injury, traumatic brain injury, Morbus Alzheimer, Parkinson, Huntington Chorea, etc.</li> <li>In vivo data on spinal cord injury model show regenerative properties</li> </ul> <p><strong>IP Rights</strong><br> PCT application 2010<br> National applications in USA/Europe 2011 <br> <br> <strong>Patent Owner</strong><br> Charité-Universitätsmedizin Berlin<br> Hannover Medical School <br><br>

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz